Tecartus denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tecartus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Issue a Quantity-Limit Denial for Tecartus

Tecartus (brexucabtagene autoleucel) is a CAR-T cell therapy that is typically administered as a single infusion. A "quantity limits" denial for Tecartus is almost always a policy structure issue: BCBS's system may flag any authorization request that doesn't match an expected unit quantity or treatment count. Because Tecartus is a custom-manufactured, single-course treatment, these denials are frequently administrative in nature and are successfully overturned on appeal when the clinical context is clearly documented.

## Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 guarantee the right to a full-and-fair internal review. The deadline to file is on your denial letter — act promptly given CAR-T therapy timelines.
• External review: After exhausting internal appeal — or if BCBS misses its response deadline — you may request an independent external review. Most ACA-compliant plans allow this for approximately four months after the final internal denial.
• Expedited review: If your hematologist-oncologist certifies that delay would seriously jeopardize your health, request expedited review for a legally required 72-hour turnaround.

## What to Include in Your Appeal

1. FDA label reference: The current FDA-approved label for Tecartus describes the dosing regimen. Include this to demonstrate that the prescribed course aligns with the approved labeling. 2. Prescriber justification letter: Your treating oncologist should explain the prescribed course of treatment and why it matches standard of care per the FDA label and relevant professional society guidance (e.g., applicable NCCN guidelines). 3. Diagnosis and treatment context: Documents confirming your diagnosis, disease stage, and treatment history that support the medical necessity of the prescribed course. 4. Clarification of single-infusion nature: A clinical note or letter clarifying that CAR-T therapy is a one-time, custom-manufactured cellular product — not a drug dispensed in repeating quantity — may resolve a system-generated quantity mismatch. 5. BCBS policy review: Obtain BCBS's published quantity-limit criteria for Tecartus and address each criterion explicitly.

## Criteria-Mapping Structure

| Quantity-Limit Criterion (from BCBS policy) | Your Documentation | |---|---| | Approved indication per FDA label | Diagnosis records | | Course of treatment per label | Prescriber letter, FDA label | | Prior authorization status | PA reference number | | Clinical necessity for prescribed course | Oncology note |

## Next Step

Request a copy of BCBS's specific quantity-limit policy for Tecartus in writing. If the denial appears to be a billing code or unit-of-service mismatch, ask the treating center's billing team to review the claim before the formal appeal is filed — this category of denial is often resolved at the billing level.